Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Open Access
- 26 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (10), 2308-2316
- https://doi.org/10.1182/bloodadvances.2019001381
Abstract
The availability and use of blinatumomab symbolizes a paradigm shift in the management of B-cell acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter cohort analysis of 239 ALL patients (227 relapsed refractory [RR], n = 227; minimal residual disease [MRD], n = 12) who received blinatumomab outside of clinical trials to evaluate safety and efficacy in the “real-world” setting. The median age of patients at blinatumomab initiation was 48 years (range, 18-85). Sixty-one (26%) patients had ≥3 prior therapies and 46 (19%) had allogeneic hematopoietic cell transplantation before blinatumomab. The response rate (complete remission/complete remission with incomplete count recovery) in patients with RR disease was 65% (47% MRD−). Among 12 patients who received blinatumomab for MRD, 9 (75%) patients achieved MRD negativity. In patients with RR disease, median relapse-free survival and overall survival (OS) after blinatumomab was 32 months and 12.7 months, respectively. Among patients who received blinatumomab for MRD, median relapse-free survival was not reached (54% MRD− at 2 years) and OS was 34.7 months. Grade ≥3 cytokine release syndrome, neurotoxicity, and hepatotoxicity were observed in 3%, 7%, and 10% of patients, respectively. Among patients who achieved complete remission/complete remission with incomplete count recovery, consolidation therapy with allogeneic hematopoietic cell transplantation retained favorable prognostic significance for OS (hazard ratio, 0.54; 95% confidence interval, 0.30-0.97; P = .04). In this largest “real-world” experience published to date, blinatumomab demonstrated responses comparable to those reported in clinical trials. The optimal sequencing of newer therapies in ALL requires further study.Keywords
This publication has 23 references indexed in Scilit:
- Single Center Real-World Experience of Daratumumab and Extra-Medullary MyelomaBlood, 2018
- Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemiaBlood Advances, 2018
- Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United StatesHaematologica, 2018
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaBlood, 2018
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2017
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2014
- Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission durationCancer, 2010
- Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study GroupHaematologica, 2010
- Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia, 2007
- Primary refractory and relapsed adult acute lymphoblastic leukemiaCancer, 1999